Ambrx
Ambrx is a pioneering biopharmaceutical company focused on discovering and developing next-generation antibody drug conjugates (ADCs) for cancer treatment. With a mission to bring targeted and stable therapies to patients with high unmet medical needs, Ambrx leverages proprietary platform technology, including expanded genetic code technology, to create innovative biologics. The company has a strong leadership team, a focus on innovation, and a pipeline of promising therapeutic candidates. As of March 7, 2024, Ambrx was acquired by Johnson & Johnson.
Industries
Nr. of Employees
medium (51-250)
Patents
Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates
US-12059473-B2
View DetailsMethods and compositions for promoting non-natural amino acid-containing protein production
US-11851662-B2
View Details
Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates
US-12059473-B2
View DetailsMethods and compositions for promoting non-natural amino acid-containing protein production
US-11851662-B2
View DetailsProducts
Expanded genetic code platform for site‑specific conjugation
A discovery platform enabling incorporation of synthetic amino acids into proteins expressed in living cells to permit highly stable, site‑specific conjugation for therapeutic biologics.
Pipeline of targeted antibody‑drug conjugate candidates for oncology
Preclinical and clinical ADC candidates targeting tumor-associated antigens using site‑specific conjugation chemistry, advanced through first‑in‑human studies and clinical presentations.
ARX517
An antibody-drug conjugate consisting of a humanized anti-PSMA monoclonal antibody covalently conjugated to two proprietary microtubule-disrupting toxins AS269, evaluated for advanced solid tumors and metastatic castration-resistant prostate cancer.
ARX788
An anti-HER2 antibody-drug conjugate evaluated in clinical studies for subjects with advanced HER2 positive breast cancer.
ARX622
A TLR7-agonist immunostiulatory antibody conjugate (ISAC) evaluated in scientific presentations.
ARX305
Preclinical oncology biologic evaluated in scientific presentations at ESMO.
Expanded genetic code platform for site‑specific conjugation
A discovery platform enabling incorporation of synthetic amino acids into proteins expressed in living cells to permit highly stable, site‑specific conjugation for therapeutic biologics.
Pipeline of targeted antibody‑drug conjugate candidates for oncology
Preclinical and clinical ADC candidates targeting tumor-associated antigens using site‑specific conjugation chemistry, advanced through first‑in‑human studies and clinical presentations.
ARX517
An antibody-drug conjugate consisting of a humanized anti-PSMA monoclonal antibody covalently conjugated to two proprietary microtubule-disrupting toxins AS269, evaluated for advanced solid tumors and metastatic castration-resistant prostate cancer.
ARX788
An anti-HER2 antibody-drug conjugate evaluated in clinical studies for subjects with advanced HER2 positive breast cancer.
ARX622
A TLR7-agonist immunostiulatory antibody conjugate (ISAC) evaluated in scientific presentations.
ARX305
Preclinical oncology biologic evaluated in scientific presentations at ESMO.
Services
Operational oversight of drug product manufacturing at CDMOs, including tech transfer support, batch record review, and coordination with QA and clinical supply chain for GMP activities.
Clinical development leadership support including clinical pharmacology strategy, PK/PD analyses, dose selection, and design of PK and drug–drug interaction studies.
Operational oversight of drug product manufacturing at CDMOs, including tech transfer support, batch record review, and coordination with QA and clinical supply chain for GMP activities.
Clinical development leadership support including clinical pharmacology strategy, PK/PD analyses, dose selection, and design of PK and drug–drug interaction studies.
Expertise Areas
- Antibody‑drug conjugate (ADC) discovery and development
- Site‑specific bioconjugation using expanded genetic code
- Oncology clinical trial management
- Clinical pharmacology and pharmacometrics
Key Technologies
- Expanded genetic code / site‑specific synthetic amino acid incorporation
- Antibody‑drug conjugates (ADCs)
- Bispecific therapeutic formats
- Immuno‑oncology conjugates